Search clinical trials for: WB-011

Total 3096 results

MedRhythms, Inc.

Active, not recruiting

Facilitators and Barriers to the Clinical Implementation of MR-001 (RhaPSody)

Chronic Stroke

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Active, not recruiting

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Sinusitis | Nasal Polyps | Polyps

China
Fervent Pharmaceuticals
ICON plc

Completed

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Vasomotor Symptoms | Menopause

United States
Asklepios Biopharmaceutical, Inc.

Active, not recruiting

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Pompe Disease

United States
Dr. Anupam Sehgal
Taysha Gene Therapies, Inc.; GlycoNet

Active, not recruiting

First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Infantile GM2 Gangliosidosis (Disorder)

Canada
Innovo Therapeutics, Inc.

Completed

First in Human, Single Ascending Dose Study

Ulcerative Colitis

Korea, Republic of
Immorna Biotherapeutics, Inc.

Active, not recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

United States
Invenux, LLC
State University of New York - Downstate Medical Center

Active, not recruiting

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

Sickle Cell Disease | Sickle-Beta Zero Thalassemia

United States
Shanghai Antengene Corporation Limited

Terminated

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors (REACH)

Advanced Solid Tumors

China
Ossium Health, Inc.

Withdrawn

Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)

GVHD,Acute
Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
Arcturus Therapeutics, Inc.

Terminated

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

SARS-CoV-2

Singapore
Adicet Bio, Inc

Enrolling by invitation

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
Abeona Therapeutics, Inc

Terminated

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Mucopolysaccharidosis III-B

United States, Germany, France
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Reduction in Hypertrophic Skin Scarring

United States
Stargazer Pharmaceuticals, Inc.

Completed

Study of STG-001 in Subjects With Stargardt Disease

Stargardt Disease-1

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Emergent Product Development Seattle LLC

Terminated

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States
Andrea Wallace
Agency for Healthcare Research and Quality (AHRQ)

Completed

Social Needs Screenings in ED

Social Determinants of Health

United States
AL-S Pharma

Unknown

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Canada
United BioSource, LLC
AveXis, Inc.

Approved for marketing

AveXis Managed Access Program Cohort for Access to AVXS-101

Spinal Muscular Atrophy

United States
Curis, Inc.

Terminated

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Cancer

United States
Minerva Neurosciences

Completed

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Healthy Subjects

Ireland
argenx

Completed

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

Cancer

Belgium
Eleven Biotherapeutics

Withdrawn

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

Diabetic Macular Edema
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

Endometriosis

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Unknown

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Advanced and/or Metastatic Solid Organ Cancer

United States
Healthpoint

Completed

Cumulative Irritation Potential of 828 Ointment

Healthy Volunteers

United States
Cerenis Therapeutics, SA

Completed

Exploratory Study of Plaque Regression (EXPRESS)

Heterozygous Familial Hypercholesterolemia

Canada
Healthpoint

Terminated

Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage

Skin Abnormalities

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Advanced Solid Tumors

United States
Norgine

Completed

A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101

Postoperative Ileus

United Kingdom
M.D. Anderson Cancer Center
Alaunos Therapeutics

Completed

Phase I Trial of ZIO-101 in Patients With Solid Tumors

Solid Tumors

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ERB-041 in Active Crohn's Disease

Crohn's Disease
Danube Pharmaceuticals, Inc.

Completed

Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure (DNB-001)

Ocular Hypertension | Glaucoma | Elevated IOP

United Kingdom
Scioderm, Inc.
Amicus Therapeutics

Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Italy, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland
Bioray Laboratories
Xiangya Hospital of Central South University; First Affiliated Hospital of... and other collaborators

Enrolling by invitation

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Beta-Thalassemia

China
Galderma R&D

Completed

A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients

Acne

Canada, France
Phoenix Molecular Imaging

Completed

PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

Prostate Cancer

United States
Dynavax Technologies Corporation
Merck Sharp & Dohme LLC

Terminated

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Melanoma | Head Neck Cancer

United States, Germany, New Zealand, Australia
ImmunityBio, Inc.

Unknown

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Squamous Cell Carcinoma

United States
Basking Biosciences, Inc.

Not yet recruiting

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) (RAISE)

Acute Ischemic Stroke
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Kythera Biopharmaceuticals

Completed

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Healthy

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Central Nervous System Neoplasm | Solid Neoplasm | Recurrent Acute Leukemia | Refractory Acute Leukemia | Infantile Fibrosarcoma

United States, Canada
NantBioScience, Inc.

Active, not recruiting

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Melanoma | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Liver Cancer

United States
Andrew Sikora
Advaxis, Inc.

Completed

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
Emerald Health Pharmaceuticals

Completed

To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Healthy

Australia
BiondVax Pharmaceuticals ltd.
Seventh Framework Programme

Completed

Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults

Healthy | Influenza

Hungary
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Neuron23 Inc.

Recruiting

A Study to Assess NEU-411 in Healthy Participants

Healthy

New Zealand

Search clinical trials for: WB-011

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations